Genfit (NASDAQ: GNFT)
Genfit Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Genfit Company Info
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
News & Analysis
Why Genfit Stock Is Skyrocketing Today
Investors applauded the company's latest clinical results.
Why Genfit Is Cratering Today
One of the company's pipeline candidates flopped in a late-stage clinical trial.
Better Buy: Intercept Pharmaceuticals or Genfit?
Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?
Can This NASH Stock Really Double Your Money?
An investment bank analyst thinks this biotech stock is worth more than twice its recent price.
3 Top Small-Cap Biotech Stocks for Aggressive Investors
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
3 Top Stocks That Aren't on Wall Street's Radar
Genfit, Changyou, and Children's Place aren't turning heads on Wall Street quite yet, but that could change very soon.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.